Total Payments
$78,655
2024 Payments
$10,457
Companies
12
Transactions
60
Medicare Patients
909
Medicare Billing
$166,148
Payment Breakdown by Category
Travel$31,564 (40.1%)
Consulting$20,458 (26.0%)
Other$20,289 (25.8%)
Research$4,989 (6.3%)
Food & Beverage$1,177 (1.5%)
Education$178.03 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $31,564 | 7 | 40.1% |
| Consulting Fee | $20,458 | 8 | 26.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,384 | 5 | 10.7% |
| Honoraria | $7,905 | 5 | 10.1% |
| Unspecified | $4,989 | 3 | 6.3% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,000 | 1 | 5.1% |
| Food and Beverage | $1,177 | 19 | 1.5% |
| Education | $178.03 | 12 | 0.2% |
Payments by Type
General
$73,666
57 transactions
Research
$4,989
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $34,986 | 9 | $0 (2022) |
| Stemline Therapeutics Inc. | $14,381 | 9 | $0 (2024) |
| West-Ward Pharmaceuticals | $9,645 | 2 | $0 (2018) |
| F. Hoffmann-La Roche AG | $9,373 | 7 | $0 (2021) |
| Ipsen Bioscience Inc | $6,640 | 5 | $0 (2019) |
| Athenex Pharmaceutical Division, LLC | $1,625 | 3 | $0 (2021) |
| R-Pharm US LLC | $1,505 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $238.27 | 6 | $0 (2018) |
| PFIZER INC. | $218.81 | 12 | $0 (2023) |
| Covidien LP | $18.60 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,457 | 3 | Stemline Therapeutics Inc. ($10,373) |
| 2023 | $2,669 | 7 | Stemline Therapeutics Inc. ($2,560) |
| 2022 | $16,170 | 7 | Hikma Pharmaceuticals USA ($16,008) |
| 2021 | $5,620 | 5 | F. Hoffmann-La Roche AG ($3,686) |
| 2020 | $2,303 | 4 | F. Hoffmann-La Roche AG ($1,303) |
| 2019 | $28,825 | 17 | Hikma Pharmaceuticals USA ($18,978) |
| 2018 | $9,851 | 10 | West-Ward Pharmaceuticals ($9,645) |
| 2017 | $2,759 | 7 | F. Hoffmann-La Roche AG ($2,633) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/02/2024 | R-Pharm US LLC | Ixempra (Drug) | Food and Beverage | Cash or cash equivalent | $83.52 | General |
| Category: Oncology | ||||||
| 02/29/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $640.00 | General |
| Category: Oncology | ||||||
| 01/10/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Consulting Fee | Cash or cash equivalent | $9,733.33 | General |
| Category: Oncology | ||||||
| 10/20/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.20 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $640.00 | General |
| Category: Oncology | ||||||
| 10/03/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $560.00 | General |
| Category: Oncology | ||||||
| 06/03/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $52.70 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| Category: Oncology | ||||||
| 03/15/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| Category: Oncology | ||||||
| 12/06/2022 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $149.72 | General |
| Category: Oncology | ||||||
| 08/17/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2022 | Hikma Pharmaceuticals USA | — | Travel and Lodging | In-kind items and services | $10,578.27 | General |
| 05/13/2022 | Hikma Pharmaceuticals USA | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
| 05/13/2022 | Hikma Pharmaceuticals USA | — | Travel and Lodging | In-kind items and services | $260.00 | General |
| 05/13/2022 | Hikma Pharmaceuticals USA | — | Travel and Lodging | In-kind items and services | $100.00 | General |
| 05/13/2022 | Hikma Pharmaceuticals USA | — | Food and Beverage | In-kind items and services | $70.00 | General |
| 12/10/2021 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2021 | Stemline Therapeutics Inc. | — | Honoraria | Cash or cash equivalent | $1,280.00 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/31/2021 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $3,685.54 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER • Category: BioOncology | ||||||
| 02/28/2021 | Athenex Pharmaceutical Division, LLC | — | Honoraria | Cash or cash equivalent | $625.00 | General |
| 12/31/2020 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $817.78 | Research |
| Study: PATRICIA • Category: BioOncology | ||||||
| 10/11/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Perjeta (Biological) | — | In-kind items and services | $485.56 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST AN OPEN-LABEL, MULTICENTER, PHASE II STUDY OF HIGH-DOSE HERCEPTIN WITH PERJETA IN PATIENTS WITH CENTRAL NERVOUS SYSTEM METASTASES FROM HER2 POSITIVE METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | $4,171 | 2 |
| PATRICIA | F. Hoffmann-La Roche AG | $817.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 174 | 350 | $187,888 | $38,009 |
| 2022 | 5 | 234 | 435 | $214,683 | $48,263 |
| 2021 | 6 | 286 | 470 | $213,778 | $50,410 |
| 2020 | 5 | 215 | 344 | $150,848 | $29,467 |
Total Patients
909
Total Services
1,599
Medicare Billing
$166,148
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 129 | 304 | $162,374 | $32,426 | 20.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 33 | 33 | $22,038 | $4,622 | 21.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 12 | 13 | $3,476 | $960.58 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 151 | 324 | $166,473 | $35,668 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 35 | 35 | $21,950 | $5,263 | 24.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 18 | $10,560 | $2,839 | 26.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 35 | $9,905 | $2,790 | 28.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 18 | 23 | $5,795 | $1,704 | 29.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 165 | 319 | $158,259 | $35,120 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 49 | 49 | $29,028 | $7,337 | 25.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 25 | 36 | $8,847 | $2,644 | 29.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 28 | $7,924 | $2,371 | 29.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 27 | $6,552 | $1,977 | 30.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $3,168 | $960.30 | 30.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 130 | 235 | $112,569 | $19,514 | 17.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 34 | 34 | $18,888 | $4,285 | 22.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 34 | $9,622 | $2,970 | 30.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 24 | 24 | $5,682 | $1,579 | 27.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 16 | 17 | $4,087 | $1,119 | 27.4% |
About Dr. Nuhad Ibrahim, M.D
Dr. Nuhad Ibrahim, M.D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528153715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nuhad Ibrahim, M.D has received a total of $78,655 in payments from pharmaceutical and medical device companies, with $10,457 received in 2024. These payments were reported across 60 transactions from 12 companies. The most common payment nature is "Travel and Lodging" ($31,564).
As a Medicare-enrolled provider, Ibrahim has provided services to 909 Medicare beneficiaries, totaling 1,599 services with total Medicare billing of $166,148. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 10/04/2006
- Last Updated 07/05/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1528153715
Products in Payments
- Oncology TA (Drug) $28,623
- ELZONRIS (Drug) $9,901
- Perjeta (Biological) $6,740
- ONIVYDE (Drug) $6,640
- Orserdu (Drug) $3,200
- Herceptin (Biological) $2,633
- Ixempra (Drug) $1,505
- Oral Paclitaxel (Drug) $1,000
- IBRANCE (Drug) $207.76
- superDimension (Device) $18.60
- KEYTRUDA (Biological) $12.15
- TALZENNA (Drug) $11.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763